SGLT2阻害薬の臨床効果を正確に検討するため，2型糖尿病症例に24時間蓄尿を行いつつtofogliflozin 20mgを24週間投与した。結果，24時間蓄尿量（mL/日）は1,790±760から2,420±540，尿糖排泄量（g/日）は20±21から125±61，体重（kg）は80.7±12.3から75.7±11.6と著明な変化を認めた。HbA1c（％）は7.88±0.94から7.63±1.29と軽度改善，HDL-コレステロール，γ-GTP，収縮期血圧は有意な改善を認めたが，ヘマトクリットや血中総ケトン体は有意に増加を認めた。蓄尿量が増加した5例では，投与前の蓄尿量が有意に少なく，尿浸透圧は高かった。また尿糖排泄量とHbA1c，グリコアルブミンには強い相関も認められた。実臨床のデータとしては既報と異なる所見もあり，また24時間蓄尿検査結果から得られる知見も少なからず認め，今後さらなる検討が望まれる。

   To investigate the exact effects of SGLT2 inhibitor, tofogliflozin was administered to 11 patients with type 2 diabetes mellitus while performing 24-hour accumulated urine analysis. The 24-hour urine volume significantly increased from 1,790±760 to 2,420±540 mL/day and 24-hour urine glucose also significantly increased from 20±21 to 125±61 g/day. Body weight significantly decreased from 80.7±12.3 to 75.7±11.6 kg. HbA1c level changed from 7.88±0.94 to 7.63±1.29, but there was no significant difference. On the other hand, HDL-cholesterol, γGTP, and systolic blood pressure levels significantly improved. The levels of hematocrit and total ketone body significantly increased. In the five cases where 24-hour urine volume increased, significantly low urine volume and high osmolality before administration of tofogliflozin were shown. A significant relationship between 24-hour urine glucose and HbA1c or glycoalbumin was observed. Because there is little difference between these clinical results and previous reports, further examination on 24-hour accumulated urine analysis should be conducted in the future.